Biogen: positive Phase 3 data in lupus

Published: 2025-06-12 08:39:27 ET BIIB

Published on 06/12/2025 at 08:39

Biogen and UCB have announced additional detailed results from the Phase 3 PHOENYCS GO study evaluating their investigational drug dapirolizumab pegol (DZP) at the annual meeting of the European League Against Rheumatism (EULAR) in Barcelona, Spain. DZP demonstrated significant clinical improvements in disease activity in people with moderate to severe systemic lupus erythematosus (SLE) at week 48, the primary endpoint. Improvements were also seen in other clinical measures, including fatigue and disease activity/remission.The safety and efficacy of DZP in LED have not been established, and its use in this disease is not approved by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is underway to confirm the results of the PHOENYCS GO study. Copyright (c) 2025 CercleFinance.com. All rights reserved.